2 stories from 2 sources
Day’s Recap is unavailable for this topic and date. Feel free to go through our curated list of stories below.
A curated list of other prominent stories from this day.
Meta is reportedly beginning to unwind its $2 billion acquisition of Manus after Chinese authorities ordered the transaction reversed. The company is said to be taking steps to dismantle the deal structure rather than proceeding toward closing.
8:03 PMTechCrunchGSK agreed to buy a biotech company for $10.6bn, its largest biotech acquisition in more than 25 years. The deal is positioned as a major push to expand GSK's cancer portfolio and future growth drivers.
12:00 AMFinancial TimesSummary
Meta is reportedly beginning to unwind its $2 billion acquisition of Manus after Chinese authorities ordered the transaction reversed. The company is said to be taking steps to dismantle the deal structure rather than proceeding toward closing.
Why it matters
Regulators are increasingly dictating M&A outcomes after announcement, raising the probability that geopolitics, not price, determines whether deals survive.
Summary
GSK agreed to buy a biotech company for $10.6bn, its largest biotech acquisition in more than 25 years. The deal is positioned as a major push to expand GSK's cancer portfolio and future growth drivers.
Why it matters
A $10.6bn oncology acquisition resets expectations for GSK's growth plan and can tighten the M&A market for cancer assets across pharma.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!